Handok Introduces Saxenda Ingredient-Based Obesity Treatment Drug to Domestic Market

Handok announced on the 24th that it has signed an exclusive domestic sales and distribution agreement with India's Biocon for the liraglutide-based obesity treatment drug Saxenda.

Handok CI [Photo by Handok]

Saxenda is an obesity treatment drug in the glucagon-like peptide (GLP)-1 class developed by Novo Nordisk. Biocon recently received approval last month for a biosimilar of Saxenda. Through this agreement, Handok plans to handle the domestic product approval, sales, and distribution of liraglutide-based obesity treatment drugs. In terms of the drug, the plan is to seek approval as a data-submission drug in the form of a synthetic chemical drug rather than the existing protein-based biologics.

Kim Young-jin, Chairman of Handok, said, “Liraglutide was mainly used as a diabetes treatment but has gained significant attention as it was launched as an obesity treatment ingredient,” adding, “Through cooperation with Biocon, Handok can expand its portfolio into the obesity field.”

This content was produced with the assistance of AI translation services.